Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Comment by Sdmsdmon Apr 24, 2016 11:14am
169 Views
Post# 24803773

RE:RE:RE:Sales Questions

RE:RE:RE:Sales Questions
lscfa wrote: Q4 cos was 21,294....Q4 gross revenue was 449,686 or 21.12 x cos .....Q4 net revenue was 47,663 or 2.24 x cos.....it is hard to believe that a co. can markup its cos by 21x in a competitive environment...I think net sales is closer to reality



The accounting standards allow for rebates to be netted off to come up with a net sales number so NO a small cost of sales did not generate a large gross sales number in reality. Its just accounting fudges. Q4 Cost of Sales (per page 8 of MD&A) was $12,757 giving a GM% on net sales of 73%. Inventory used to generate $449k of gross sales was about $95k giving a GM% of ~78% (excl.CMI's) so same ball park.

It all depends whether you think customer marketing incentives will continue to run at 90% (like that halfwit Ivey) of sales or whether after some initial upfront payments to secure business they will fall back to a more reasonable number.

I think they will fall back significantly (30%-50%??) on a per customer basis (depending on whether its independents or chains) but they will always be present because the business will always be winning and looking to retain business. Irrespective at this early stage I think some of the other posters are right , Gross sales, sales teams and product portfolio are the right metrics to focus on. 



Bullboard Posts